Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Sijunzi decoction (MSJZD) is a Traditional Chinese Medicine (TCM) herbal formula derived from the classic Sijunzi decoction (Four Gentlemen Decoction). It is primarily used as an adjunctive therapy to strengthen the spleen and replenish qi in patients with chronic conditions. In oncology, MSJZD is investigated for its ability to inhibit the JAK1-STAT3 signaling pathway and core targets such as EGFR, SRC, and AKT1, thereby reducing M2 macrophage infiltration and increasing CD8+ T cell activity to reverse the immunosuppressive tumor microenvironment. It is also utilized in the treatment of ulcerative colitis in remission, where it is formulated with specific herbs like Radix pseudostellariae, Atractylodes macrocephala, and Poria to regulate gastrointestinal motility and enhance intestinal mucosal immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified sijunzi decoction.